胎盘腺信号的升高有助于孕前的发病
Takayuki Iriyama1, Kaiqi Sun1, Nicholas F Parchim1
1From Departments of Biochemistry and Molecular Biology (T.I., K.S., N.F.P., J.L., C.Z., A.S., M.R.B., R.E.K., Y.X.) and Department of Obstetrics, Gynecology, and Reproductive Sciences (L.A.H., S.C.B., B.M.S.), University of Texas Medical School at Houston: Department of Obstetrics and Gynecology, Faculty of Medicine, University of Tokyo, Japan (T.I.); Graduate School of Biomedical Sciences, University of Texas, Houston (K.S., N.F.P., M.R.B, R.E.K., Y.X.); Department of Urology (C.Z.), Xiangya Hospital of Central South University, Changsha, Hunan, China; Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, (L-N. L.C., T.-S.C.); and Department of Pathology, Texas Children's Hospital, Houston (M.J.H.).
长期升高的胎盘腺,由CD73驱动,导致孕前的特征. 过度的A2B腺受体 (ADORA2B) 信号加剧了这种妊娠高血压障碍,揭示了新的治疗点.
科学领域:
- 产科和妇科 产科和妇科
- 心血管研究研究心血管研究
- 分子医学是分子医学.
背景情况:
- 孕前是全球主要的孕产妇和新生儿死亡原因之一.
- 胎盘异常是可疑的原因,但潜在的机制仍然不清楚.
研究的目的:
- 为了研究胎盘腺在产前病原发生中的作用.
- 确定将胎盘功能障碍与母亲症状联系起来的分子途径.
主要方法:
- 利用了两个不同的生殖前的小鼠模型.
- 采用遗传和药理学策略来调节腺信号传递.
- 分析了人类和小鼠的胎盘组织.
主要成果:
- 胎盘腺含量升高诱导孕前的特征:高血压,蛋白尿,胎儿生长限制和血管功能障碍.
- 过度的A2B腺受体 (ADORA2B) 信号加剧了孕前的特征.
- 增加的胎盘CD73被确定为增加胎盘腺的关键酶.
结论:
- 胎盘腺信号传递是孕前的新型致病因子.
- 通过CD73介导的腺升高和ADORA2B信号传递有助于孕前的病理生理学.
- 确定了孕前治疗的新型治疗点.
更多相关视频
12:17The 4-vessel Sampling Approach to Integrative Studies of Human Placental Physiology In Vivo
Published on: August 2, 2017
12:02Human Primary Trophoblast Cell Culture Model to Study the Protective Effects of Melatonin Against Hypoxia/reoxygenation-induced Disruption
Published on: July 30, 2016
相关概念视频
Hormonal Regulation
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
GPCRs Regulate Adenylyl Cylase Activity
cAMP-dependent Protein Kinase Pathways
Teratogenicity
Adrenergic Antagonists: ɑ and β-Receptor Blockers
